| Project/Area Number |
18K16547
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55060:Emergency medicine-related
|
|---|
| Research Institution | Nippon Medical School |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2021: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Keywords | 配合変化試験 / 濁度 / HPLC / 集中治療 / 注射薬 / 多剤配合変化試験 / 配合変化 / pH / 注射 / 残存率 |
|---|
| Outline of Final Research Achievements |
The study is to conduct a multi-drug compatibility test based on the use of injectable drugs in the emergency and intensive care. Then, a multi-drug compatibility chart should be created and used clinically. The 3-drug compatibility test was conducted in 157 tests, revealing that the combination of “rocuronium - insulin human - heparin” caused incompatibility. In addition, it was clarified that combination of vasopressin and catecholamine drugs decreased the content of vasopressin. In addition, we clarified that sodium sulfite, an additive for catecholamine drugs, reduces the residual drug rate of vasopressin. From these compatibility tests, we created the compatibility chart and succeeded in using it clinically.
|
| Academic Significance and Societal Importance of the Research Achievements |
救急・集中治療領域では、多くの注射薬が同一ルート内で配合されて投与されており、配合変化の危険性が高い。同一ルートで投与できるか判断するために配合変化試験を実施して評価し、その試験情報をデータベース化し医療現場へ還元した。本結果により、安全な注射薬の点滴ルート選択を実施することができ、より効果的で安全な薬物療法の提供が可能となった。
|
